Cara Care for IBS
Commercial- Indications
- Irritable bowel syndrome
Company intelligence / Profile preview
The Cara Care digital therapeutic app has demonstrated high user engagement and clinical benefit in managing digestive diseases. It has a reported treatment success rate of nearly 79% among users with conditions such as IBS, IBD, GERD, and food intolerances. The program combines medication tracking with dietary and psychological interventions. It was the first prescribed digital health application reimbursed by German statutory health insurance for IBS. Clinical results support improved patient outcomes when used alongside standard care.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cara Care.